Table 5.
Hepatic Arterial Infusion (HAI).
| Study | Year, Location | Study Design | # of Patients | Objective Response Rate, % | Median OS, mo | Median PFS, mo | EHD | Chemotherapy Regimen |
|---|---|---|---|---|---|---|---|---|
| Maes et al. (53) | 2008, Belgium | Retrospective | 30 | 33.3 | 7.3 | 3 | 19 | MMC |
| Nielson et al. (54) | 2012, Denmark | Prospective | 16 | 50 | 19.2 | 7.9 | 14 | Oxaliplatin |
| Tewes et al. (55) | 2017, Germany | Retrospective | 70 | 20 | 7 | 2 | 62 | Mitomycin and melphalane |
| Hsaio et al. (56) | 2018, Taiwan | Retrospective | 42 | 47 | 19.3 | 8.4 | – | Mitoxantrone, folinic acid, 50FU, and cisplatinum |
| Furuta et al. (57) | 2020, Japan | Retrospective | 57 | 63 | 11.3 | – | – | 5-fu, epirubicin, and MMC |
Demonstrates various chemotherapy regimen.